Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Core Viewpoint - Zevra Therapeutics, Inc. has granted an equity inducement award to its new Chief Financial Officer, Justin Renz, as part of its strategy to attract talent and enhance its leadership team [1][2]. Group 1: Equity Inducement Award - The company granted Mr. Renz an option to purchase 300,000 shares of common stock with a 10-year term and an exercise price of $9.55, which reflects the closing price on March 18, 2026 [2]. - The option will vest over four years, contingent upon Mr. Renz's continued service [2]. Group 2: Company Overview - Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases, with a late-stage pipeline aimed at delivering life-changing treatments [3]. - The company is committed to expanding access through geographic opportunities and progressing its pipeline towards key milestones, with its lead product targeting Niemann-Pick disease type C (NPC) [3]. - Zevra's strategic plan emphasizes patient centricity, integrity, accountability, innovation, and courage to deliver long-term value [3].